Speakers

 

 

The Advisory Board

 

We’re proud to work alongside a stellar line up of Orphan Drug and Gene Therapy Professionals who have helped us curate the most up to date and relevant program for you.

200 World Leading Speakers

 

2019 Speakers

Bringing together industry leaders from across the orphan drug and cell and gene therapy industries.

 

Annemieke Aartsma Rus, Professor of Translational Genetics, Department of Human Genetics, Leiden University Medical Center

Annemieke Aartsma Rus | Professor of Translational Genetics, Department of Human Genetics | Leiden University Medical Center » speaking at Orphan Drug Congress

Karen Aiach, Chief Executive Officer, Lysogene

Karen Aiach | Chief Executive Officer | Lysogene » speaking at Orphan Drug Congress

Dennis Akkaya, Corporate Development, myTomorrows

Dennis Akkaya | Corporate Development | myTomorrows » speaking at Orphan Drug Congress

Luca Alberici, Chief Business Officer, MolMed

Luca Alberici | Chief Business Officer | MolMed » speaking at Orphan Drug Congress

Sofie Alverlind, Project Manager, Swedish Association of Local Authorities and Regions

Sofie Alverlind | Project Manager | Swedish Association of Local Authorities and Regions » speaking at Orphan Drug Congress

Einar Andreassen, Senior Adviser, Norwegian Medicines Agency

Einar Andreassen | Senior Adviser | Norwegian Medicines Agency » speaking at Orphan Drug Congress

Aris Angelis, Research Officer, Medical Technology Research Group, London School of Economics and Political Science

Aris Angelis | Research Officer, Medical Technology Research Group | London School of Economics and Political Science » speaking at Orphan Drug Congress

Diego Ardigo, R&D Rare Diseases Unit Head, CHIESI Farmaceutici Spa

Diego Ardigo | R&D Rare Diseases Unit Head | CHIESI Farmaceutici Spa » speaking at Orphan Drug Congress

Francis Arickx, Head of the Directorate Reimbursement of Medicines and Pharmaceutical Policy,, National Institute for Health and Disability Insurance RIZIV-INAMI

Francis Arickx | Head of the Directorate Reimbursement of Medicines and Pharmaceutical Policy, | National Institute for Health and Disability Insurance RIZIV-INAMI » speaking at Orphan Drug Congress

Dr Segolene Ayme, Founder of Orphanet & Rare Disease Expert in Residence, Inserm

Dr Segolene Ayme | Founder of Orphanet & Rare Disease Expert in Residence | Inserm » speaking at Orphan Drug Congress

Jasmin Barman, Scientific Advisor, SGP

Jasmin Barman | Scientific Advisor | SGP » speaking at Orphan Drug Congress

Denis Belyakov, Executive Director, Union of Patients? And Patients? Organizations With Rare Diseases

Denis Belyakov | Executive Director | Union of Patients? And Patients? Organizations With Rare Diseases » speaking at Orphan Drug Congress

Marian Bendik, Head of Gene Therapy, Process Development, Shire

Marian Bendik | Head of Gene Therapy, Process Development | Shire » speaking at Orphan Drug Congress

Annika Bergman, Pricing and Market Access Europe, Sarepta International Holdings GmbH

Annika Bergman | Pricing and Market Access Europe | Sarepta International Holdings GmbH » speaking at Orphan Drug Congress

Dr Michael Binks, VP, Rare Disease Clinical Research, Pfizer

Dr Michael Binks | VP, Rare Disease Clinical Research | Pfizer » speaking at Orphan Drug Congress

Catalin Bobirca, Medical Franchise Head, Rare Diseases, Oncology Region Europe, Novartis

Catalin Bobirca | Medical Franchise Head, Rare Diseases, Oncology Region Europe | Novartis » speaking at Orphan Drug Congress

Mathieu Boudes, Coordinator of PARADIGM, European Patients' Forum

Mathieu Boudes | Coordinator of PARADIGM | European Patients' Forum » speaking at Orphan Drug Congress

Dr Meriem Bouslouk, Orphan drug policy adviser for Germany

Dr Meriem Bouslouk |  | Orphan drug policy adviser for Germany » speaking at Orphan Drug Congress

Meriem Bouslouk, Orphan drug policy adviser for Germany

Meriem Bouslouk |  | Orphan drug policy adviser for Germany » speaking at Orphan Drug Congress

Jacoline Bouvy, Senior Scientific Adviser, National Insitute for Health and Care Excellence

Jacoline Bouvy | Senior Scientific Adviser | National Insitute for Health and Care Excellence » speaking at Orphan Drug Congress

Sophia Brodin, Deputy Head of Department, Department of Value Based Pricing, The Dental and Pharmaceutical Benefits Agency T.L.V.

Sophia Brodin | Deputy Head of Department, Department of Value Based Pricing | The Dental and Pharmaceutical Benefits Agency T.L.V. » speaking at Orphan Drug Congress

Nicholas Brooke, Executive Director, Patient Focused Medicines Development

Nicholas Brooke | Executive Director | Patient Focused Medicines Development » speaking at Orphan Drug Congress

Virginie Bros-Facer, Scientific Director, EURORDIS

Virginie Bros-Facer | Scientific Director | EURORDIS » speaking at Orphan Drug Congress

Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)

Anna Bucsics | Project Advisor | Mechanism of Coordinated Access to orphan medicinal products (MoCA) » speaking at Orphan Drug Congress

Dr Andreas Busch, Chief Scientific Officer, Head of Research and Development, Shire Pharmaceuticals

Dr Andreas Busch | Chief Scientific Officer, Head of Research and Development | Shire Pharmaceuticals » speaking at Orphan Drug Congress

Clara Campàs, Partner, Asabys Partners

Clara Campàs | Partner | Asabys Partners » speaking at Orphan Drug Congress

Agnese Cangini, Health Economist, AIFA

Agnese Cangini | Health Economist | AIFA » speaking at Orphan Drug Congress

Nathalie Cartier, Director, Institut National De La sante Et De La Recherche Medicale

Nathalie Cartier | Director | Institut National De La sante Et De La Recherche Medicale » speaking at Orphan Drug Congress

Fleur Chandler, Therapy Area Head of Respiratory Value Evidence and Outcomes, GlaxoSmithKline Biologicals

Fleur Chandler | Therapy Area Head of Respiratory Value Evidence and Outcomes | GlaxoSmithKline Biologicals » speaking at Orphan Drug Congress

Maria Chatzou, Co-founder & Senior Advisor, Innovation Forum

Maria Chatzou | Co-founder & Senior Advisor | Innovation Forum » speaking at Orphan Drug Congress

James Christie, SVP Manufacturing and Supply Chain, MeiraGTx

James Christie | SVP Manufacturing and Supply Chain | MeiraGTx » speaking at Orphan Drug Congress

Gabriel Cohn, Vice President Of Clinical Development Lead, Avrobio

Gabriel Cohn | Vice President Of Clinical Development Lead | Avrobio » speaking at Orphan Drug Congress

Laura Cox, UK Country Lead and Business Development, myTomorrows

Laura Cox | UK Country Lead and Business Development | myTomorrows » speaking at Orphan Drug Congress

Emily Crossley, Co-founder, Duchenne U.K.

Emily Crossley | Co-founder | Duchenne U.K. » speaking at Orphan Drug Congress

Avril Daly, CEO, Retina International

Avril Daly | CEO | Retina International » speaking at Orphan Drug Congress

Tagle Danilo, Associate Director for Special Initiatives, National Center for Advancing Translational Sciences

Tagle Danilo | Associate Director for Special Initiatives | National Center for Advancing Translational Sciences » speaking at Orphan Drug Congress

Cecile De Coster, Director Regulatory Science, Bluebird Bio

Cecile De Coster | Director Regulatory Science | Bluebird Bio » speaking at Orphan Drug Congress

Dr Sjef De Kimpe, Co-founder and SVP R&D, Auxesia Orion

Dr Sjef De Kimpe | Co-founder and SVP R&D | Auxesia Orion » speaking at Orphan Drug Congress

Professor Michele De Luca, Scientist, Professor, University of Modena e Reggio Emilia

Professor Michele De Luca | Scientist, Professor | University of Modena e Reggio Emilia » speaking at Orphan Drug Congress

Laura De Rosa, Collaborator & Co-author, University of Modena e Reggio Emilia

Laura De Rosa | Collaborator & Co-author | University of Modena e Reggio Emilia » speaking at Orphan Drug Congress

Dr Renato Dellamano, President, Medical Marketing Economics

Dr Renato Dellamano | President | Medical Marketing Economics » speaking at Orphan Drug Congress

Lisa Dilworth, Vice President Rare and Orphan Diseases, Synteract

Lisa Dilworth | Vice President Rare and Orphan Diseases | Synteract » speaking at Orphan Drug Congress

Scott Dorfman, President & CEO, Odylia Therapeutics

Scott Dorfman | President & CEO | Odylia Therapeutics » speaking at Orphan Drug Congress

Cinzia Dorigo, Executive Director Clinical Development, Syneos Health

Cinzia Dorigo | Executive Director Clinical Development | Syneos Health » speaking at Orphan Drug Congress

Dr Cynthia Dukes, Vice President, Drug Development, Rare Disease, ICON plc

Dr Cynthia Dukes | Vice President, Drug Development, Rare Disease | ICON plc » speaking at Orphan Drug Congress

Rudy Dupree, Senior Project Manager, EUnetHTA WP4, EUnetHTA

Rudy Dupree | Senior Project Manager, EUnetHTA WP4 | EUnetHTA » speaking at Orphan Drug Congress

Jami Ellis, Executive Director of Commercial Development, Horizon Pharma

Jami Ellis | Executive Director of Commercial Development | Horizon Pharma » speaking at Orphan Drug Congress

Erik Emerson, Executive Vice President, Commercial Operations, Mezzion Pharma

Erik Emerson | Executive Vice President, Commercial Operations | Mezzion Pharma » speaking at Orphan Drug Congress

Van Zyl Engelbrecht, Clinical Project Director EU, UBC

Van Zyl Engelbrecht | Clinical Project Director EU | UBC » speaking at Orphan Drug Congress

Karen Facey, Senior Research Fellow, University of Edinburgh

Karen Facey | Senior Research Fellow | University of Edinburgh » speaking at Orphan Drug Congress

Kelly Franchetti, RN, CCRN, CEN VP, Global Patient Insights & Engagement, Commercialisation & Outcomes, ICON plc

Kelly Franchetti | RN, CCRN, CEN VP, Global Patient Insights & Engagement, Commercialisation & Outcomes | ICON plc » speaking at Orphan Drug Congress

Pedro Franco, Director for Europe for Global Regulatory and Scientific Policy, Merck Serono

Pedro Franco | Director for Europe for Global Regulatory and Scientific Policy | Merck Serono » speaking at Orphan Drug Congress

Michela Gabaldo, Head of Alliance Management, Fondazione Telethon

Michela Gabaldo | Head of Alliance Management | Fondazione Telethon » speaking at Orphan Drug Congress

Benjamin Gannon, Head of International Government Affairs, Public Policy & Patient Engagement, Vertex Pharmaceuticals

Benjamin Gannon | Head of International Government Affairs, Public Policy & Patient Engagement | Vertex Pharmaceuticals » speaking at Orphan Drug Congress

Dr Caridad Pontes García, Pharmacotherapeutic Harmonization, Catalan Health Service

Dr Caridad Pontes García | Pharmacotherapeutic Harmonization | Catalan Health Service » speaking at Orphan Drug Congress

Pamela Gavin, Chief Strategy Officer, National Organization for Rare Disorders

Pamela Gavin | Chief Strategy Officer | National Organization for Rare Disorders » speaking at Orphan Drug Congress

Josie Godfrey, Director, JG Zebra Consulting

Josie Godfrey | Director | JG Zebra Consulting » speaking at Orphan Drug Congress

Rory Graham, BPharm, MBA Senior Director, Regulatory Affairs, Europe & International Region, ICON plc

Rory Graham | BPharm, MBA Senior Director, Regulatory Affairs, Europe & International Region | ICON plc » speaking at Orphan Drug Congress

Dr Tim Guilliams, CEO, Healx

Dr Tim Guilliams | CEO | Healx » speaking at Orphan Drug Congress

Dr Femida Gwadry-Sridhar, Founder and CEO, Pulse Infoframe Inc

Dr Femida Gwadry-Sridhar | Founder and CEO | Pulse Infoframe Inc » speaking at Orphan Drug Congress

Denis Horgan, Executive Director, EAPM (European Alliance for Personalised Medicine)

Denis Horgan | Executive Director | EAPM (European Alliance for Personalised Medicine) » speaking at Orphan Drug Congress

Annie Hubert, Director, European Public Policy, Alliance for Regenerative Medicine

Annie Hubert | Director, European Public Policy | Alliance for Regenerative Medicine » speaking at Orphan Drug Congress

Lynne Hughes, Vice President & Head, Centre of Excellence, Neurology, Therapeutic & Speciality Business Development, IQVIA

Lynne Hughes | Vice President & Head, Centre of Excellence, Neurology, Therapeutic & Speciality Business Development | IQVIA » speaking at Orphan Drug Congress

Wills Hughes-Wilson, Head of Patient Access & Commercial Planning, Mereo BioPharma

Wills Hughes-Wilson | Head of Patient Access  & Commercial Planning | Mereo BioPharma » speaking at Orphan Drug Congress

Adam Hutchings, Managing Director, Dolon

Adam Hutchings | Managing Director | Dolon » speaking at Orphan Drug Congress

Dr Carlo Incerti, SVP, Head of Global Medical Affairs, CMO, Genzyme, A Sanofi Company

Dr Carlo Incerti | SVP, Head of Global Medical Affairs, CMO | Genzyme, A Sanofi Company » speaking at Orphan Drug Congress

Edmund Jessop, Medical Adviser, National Health Service

Edmund Jessop | Medical Adviser | National Health Service » speaking at Orphan Drug Congress

Bodil Jonason, Vice President, Marketing and Sales, Inceptua

Bodil Jonason | Vice President, Marketing and Sales | Inceptua » speaking at Orphan Drug Congress

M Ken Kengatharan, Managing Partner, Atheneos Ventures and CEO, Auxesia Orion

M Ken Kengatharan | Managing Partner, Atheneos Ventures and CEO | Auxesia Orion » speaking at Orphan Drug Congress

Alastair Kent Obe, Former Director, Genetic Alliance UK, Retired

Alastair Kent Obe | Former Director, Genetic Alliance UK | Retired » speaking at Orphan Drug Congress

Diane Kleinermans, Advisor to the Ministry of Health and Social Affairs, Belgian Federal Government

Diane Kleinermans | Advisor to the Ministry of Health and Social Affairs | Belgian Federal Government » speaking at Orphan Drug Congress

Nicolas Koebel, Head of Program & Portfolio Management, Orchard Therapeutics

Nicolas Koebel | Head of Program & Portfolio Management | Orchard Therapeutics » speaking at Orphan Drug Congress

Maryna Kolochavina, Project Director, Real World & Late Phase, Syneos Health

Maryna Kolochavina | Project Director, Real World & Late Phase | Syneos Health » speaking at Orphan Drug Congress

Daan Kranenburg, VP Commercial Operations Europe, bluebird bio

Daan Kranenburg | VP Commercial Operations Europe | bluebird bio » speaking at Orphan Drug Congress

Jennifer Lambe, Senior Project Manager, ICON plc

Jennifer Lambe | Senior Project Manager | ICON plc » speaking at Orphan Drug Congress

Dr Greg Larosa, Senior Vice President & Head of Scientific Strategy, Rare Disease RU, Pfizer

Dr Greg Larosa | Senior Vice President & Head of Scientific Strategy, Rare Disease RU | Pfizer » speaking at Orphan Drug Congress

Yann Le Cam, Chief Executive Officer, EURORDIS

Yann Le Cam | Chief Executive Officer | EURORDIS » speaking at Orphan Drug Congress

Bastiaan Leewis, MSAT Manager Industrialization, MeiraGTx

Bastiaan Leewis | MSAT Manager Industrialization | MeiraGTx » speaking at Orphan Drug Congress

Sune Lindgaard, Chief of Business Intelligence, Amgros, Denmark

Sune Lindgaard | Chief of Business Intelligence | Amgros, Denmark » speaking at Orphan Drug Congress

Yolanda Ludena, Foundation twenty-nine

Yolanda Ludena |  | Foundation twenty-nine » speaking at Orphan Drug Congress

Alastair Mackinnon, CMO, Mereo BioPharma

Alastair Mackinnon | CMO | Mereo BioPharma » speaking at Orphan Drug Congress

Dr William Maier, PhD, MPH Chief Scientific Officer & Head, Rare Disease Research, Commercialisation and Outcomes, ICON plc

Dr William Maier | PhD, MPH Chief Scientific Officer & Head, Rare Disease Research, Commercialisation and Outcomes | ICON plc » speaking at Orphan Drug Congress

Marc Martinell, CEO, Minoryx Therapeutics

Marc Martinell | CEO | Minoryx Therapeutics » speaking at Orphan Drug Congress

Camille Metais, Senior Regulatory Affairs Director, Alexion Pharma LLC

Camille Metais | Senior Regulatory Affairs Director | Alexion Pharma LLC » speaking at Orphan Drug Congress

Ana Mingorance, Chief Development Officer, Loulou Foundation

Ana Mingorance | Chief Development Officer | Loulou Foundation » speaking at Orphan Drug Congress

Eva Molero, CEO, Synapse Research Management Partners

Eva Molero | CEO | Synapse Research Management Partners » speaking at Orphan Drug Congress

Nathalie Moll, Director General, EFPIA

Nathalie Moll | Director General | EFPIA » speaking at Orphan Drug Congress

Arlete Monteiro, IT Director, Ministry Of Health Of Portugal

Arlete Monteiro | IT Director | Ministry Of Health Of Portugal » speaking at Orphan Drug Congress

Dr Marisol Montolio Del Olmo, Scientific Director, Duchenne Parent Project Spain

Dr Marisol Montolio Del Olmo | Scientific Director | Duchenne Parent Project Spain » speaking at Orphan Drug Congress

Dmitry Mordvintsev, Head of Specialty Care BU, Genzyme

Dmitry Mordvintsev | Head of Specialty Care BU | Genzyme » speaking at Orphan Drug Congress

Dirk Moritz, Principal, Blue Matter Consulting

Dirk Moritz | Principal | Blue Matter Consulting » speaking at Orphan Drug Congress

Dr William Motel, Regulatory Affairs Director, IQVIA

Dr William Motel | Regulatory Affairs Director | IQVIA » speaking at Orphan Drug Congress

Karl-Johan Myren, Head of Patient Access, Alexion Pharmaceuticals

Karl-Johan Myren | Head of Patient Access | Alexion Pharmaceuticals » speaking at Orphan Drug Congress

Dr Alexander Natz, Secretary General, EUCOPE

Dr Alexander Natz | Secretary General | EUCOPE » speaking at Orphan Drug Congress

Daniel O'Connor, Medical Assessor, Medicines and Healthcare Products Regulatory Agency

Daniel O'Connor | Medical Assessor | Medicines and Healthcare Products Regulatory Agency » speaking at Orphan Drug Congress

Sam Oliver, Joint Managing Director, pH Associates

Sam Oliver | Joint Managing Director | pH Associates » speaking at Orphan Drug Congress

Tuyen Ong, Chief Development Officer, Nightstar Therapeutics

Tuyen Ong | Chief Development Officer | Nightstar Therapeutics » speaking at Orphan Drug Congress

Dr Emanuele Ostuni, Head of Europe, Cell and Gene Therapy, Novartis

Dr Emanuele Ostuni | Head of Europe, Cell and Gene Therapy | Novartis » speaking at Orphan Drug Congress

Romina Oxborough, Director of Clinigen Consulting, Clinigen Group

Romina Oxborough | Director of Clinigen Consulting | Clinigen Group » speaking at Orphan Drug Congress

Dr Pan Pantziarka, Program Director, Anticancer Fund

Dr Pan Pantziarka | Program Director | Anticancer Fund » speaking at Orphan Drug Congress

Samantha Parker, Chief Patient Access Officer, Lysogene

Samantha Parker | Chief Patient Access Officer | Lysogene » speaking at Orphan Drug Congress

Andrew Parker, Executive Vice President and Chief Science Officer, Zealand Pharma

Andrew Parker | Executive Vice President and Chief Science Officer | Zealand Pharma » speaking at Orphan Drug Congress

Doug Paul, partner, Medical Marketing Economics

Doug Paul | partner | Medical Marketing Economics » speaking at Orphan Drug Congress

Tapani Piha, Head Of Unit, European Commission

Tapani Piha | Head Of Unit | European Commission » speaking at Orphan Drug Congress

Sarah Pitluck, Head, Global Pricing & Reimbursement, Spark Therapeutics

Sarah Pitluck | Head, Global Pricing & Reimbursement | Spark Therapeutics » speaking at Orphan Drug Congress

Silvia Ragno, Senior Director External Asset Lead, Takeda

Silvia Ragno | Senior Director External Asset Lead | Takeda » speaking at Orphan Drug Congress

Dr Sam Rasty, Chief Operating Officer, Homology Medicines

Dr Sam Rasty | Chief Operating Officer | Homology Medicines » speaking at Orphan Drug Congress

Kirsty Reid, Senior Manager Science Policy and Animal Welfare, EFPIA

Kirsty Reid | Senior Manager Science Policy and Animal Welfare | EFPIA » speaking at Orphan Drug Congress

Owen Roberts, Chief Executive Officer, M4K Pharma

Owen Roberts | Chief Executive Officer | M4K Pharma » speaking at Orphan Drug Congress

Dr Paul Robinson, Patient Engagement Lead, Europe, Merck Sharp and Dohme

Dr Paul Robinson | Patient Engagement Lead, Europe | Merck Sharp and Dohme » speaking at Orphan Drug Congress

Angi Robinson, Executive Director, Strategic Development, Rare Disease & Pediatrics, Premier Research

Angi Robinson | Executive Director, Strategic Development, Rare Disease & Pediatrics | Premier Research » speaking at Orphan Drug Congress

Gregory Robinson, Chief Scientific Officer, Nightstar Therapeutics

Gregory Robinson | Chief Scientific Officer | Nightstar Therapeutics » speaking at Orphan Drug Congress

Dr Jerome Rossert, Vice President, General Medicine, Global Clinical Development, Vertex Pharmaceuticals

Dr Jerome Rossert | Vice President, General Medicine, Global Clinical Development | Vertex Pharmaceuticals » speaking at Orphan Drug Congress

Delphine Roulland, Senior Manager Public Affairs chez, EUCOPE

Delphine Roulland | Senior Manager Public Affairs chez | EUCOPE » speaking at Orphan Drug Congress

Jude Samulski, Director, Professor of Pharmacology, University of North Carolina at Chapel Hill, Gene Therapy Center

Jude Samulski | Director, Professor of Pharmacology | University of North Carolina at Chapel Hill, Gene Therapy Center » speaking at Orphan Drug Congress

Luca Sangiori, Head of Medical Genetics and Rare Orthopedic Diseases, Rizzoli Orthopaedic Institute

Luca Sangiori | Head of Medical Genetics and Rare Orthopedic Diseases | Rizzoli Orthopaedic Institute » speaking at Orphan Drug Congress

Reto Schaberl, Head Business Development, Ewopharma AG

Reto Schaberl | Head Business Development | Ewopharma AG » speaking at Orphan Drug Congress

Scott Schliebner, Vice President, Scientific Affairs, Rare Diseases, PRA Health Sciences

Scott Schliebner | Vice President, Scientific Affairs, Rare Diseases | PRA Health Sciences » speaking at Orphan Drug Congress

Gabriele Schlosser-Weber, Clinical assessor, Bfarm

Gabriele Schlosser-Weber | Clinical assessor | Bfarm » speaking at Orphan Drug Congress

Dr Yvonne Schmidt, Scientific Advisor, Pharmaceuticals Department, G-BA

Dr Yvonne Schmidt | Scientific Advisor, Pharmaceuticals Department | G-BA » speaking at Orphan Drug Congress

Sophie Schmitz, Managing Partner, Partners4Access

Sophie Schmitz | Managing Partner | Partners4Access » speaking at Orphan Drug Congress

Ad Schuurman, Senior Advisor International Affairs, National Health Care Institute (ZIN), the Netherlands

Ad Schuurman | Senior Advisor International Affairs | National Health Care Institute (ZIN), the Netherlands » speaking at Orphan Drug Congress

Raghuram Selvaraju, Managing Director, Senior Analyst, Healthcare, Rodman & Renshaw

Raghuram Selvaraju | Managing Director, Senior Analyst, Healthcare | Rodman & Renshaw » speaking at Orphan Drug Congress

Daniela Settesoldi, Pharmaceutical Expenditure, Expenditure monitoring, AIFA

Daniela Settesoldi | Pharmaceutical Expenditure, Expenditure monitoring | AIFA » speaking at Orphan Drug Congress

Nick Sireau, Chairman, AKU Society

Nick Sireau | Chairman | AKU Society » speaking at Orphan Drug Congress

David Sourdive, Executive Vice President Technical Operations, Cellectis

David Sourdive | Executive Vice President Technical Operations | Cellectis » speaking at Orphan Drug Congress

Marcio Souza, Chief Operating Officer, PTC Therapeutics

Marcio Souza | Chief Operating Officer | PTC Therapeutics » speaking at Orphan Drug Congress

Leo Strican, Head of Access Value & Evidence Strategy, Europe, Bluebird Bio

Leo Strican | Head of Access Value & Evidence Strategy, Europe | Bluebird Bio » speaking at Orphan Drug Congress

Rick Thompson, CEO, Findacure

Rick Thompson | CEO | Findacure » speaking at Orphan Drug Congress

Dr Josep Torrent-Farnell, Medicines Department, Catalan Health Service

Dr Josep Torrent-Farnell | Medicines Department | Catalan Health Service » speaking at Orphan Drug Congress

Marie Trad, Executive Medical Director, IQVIA

Marie Trad | Executive Medical Director | IQVIA » speaking at Orphan Drug Congress

Dr Giuliana Vallanti, Director Of Development, Quality Control And Qualified Person, Molmed SpA

Dr Giuliana Vallanti | Director Of Development, Quality Control And Qualified Person | Molmed SpA » speaking at Orphan Drug Congress

Inneke Van De Vijver, Advisor, N.I.H.D.I.

Inneke Van De Vijver | Advisor | N.I.H.D.I. » speaking at Orphan Drug Congress

Dr Sander Van Deventer, Chief Scientific Officer And General Manager, uniQure

Dr Sander Van Deventer | Chief Scientific Officer And General Manager | uniQure » speaking at Orphan Drug Congress

Dr Andreas Vogel, Head of European Regulatory, Bluebird Bio

Dr Andreas Vogel | Head of European Regulatory | Bluebird Bio » speaking at Orphan Drug Congress

Till Voigtlander, Vice-President of the Board of Members States on ERNs, Medical University of Vienna

Till Voigtlander | Vice-President of the Board of Members States on ERNs | Medical University of Vienna » speaking at Orphan Drug Congress

Dr Birgitte Volck, Senior Vice President, Head of R&D Rare Diseases, GlaxoSmithKline

Dr Birgitte Volck | Senior Vice President, Head of R&D Rare Diseases | GlaxoSmithKline » speaking at Orphan Drug Congress

Lucia Von Bredow, Public Affairs & Patient Policy Manager, Clinigen Group

Lucia Von Bredow | Public Affairs & Patient Policy Manager | Clinigen Group » speaking at Orphan Drug Congress

Misha Votruba, Director, Gradus R.S.J. Life Sciences

Misha Votruba | Director | Gradus R.S.J. Life Sciences » speaking at Orphan Drug Congress

Darren Walsh, Senior Director - Market Access & Govt. Affairs – EU, Orchard Therapeutics

Darren Walsh | Senior Director - Market Access & Govt. Affairs – EU | Orchard Therapeutics » speaking at Orphan Drug Congress

Dr Mary Wang, Global Partnerships & Project Manager, Fondazione Telethon

Dr Mary Wang | Global Partnerships & Project Manager | Fondazione Telethon » speaking at Orphan Drug Congress

Dr Richard Wenzel, Principal, Charles River Associates

Dr Richard Wenzel | Principal | Charles River Associates » speaking at Orphan Drug Congress

Magdalena Wladysiuk, Owner And Vice President, HTA Consulting

Magdalena Wladysiuk | Owner And Vice President | HTA Consulting » speaking at Orphan Drug Congress

Pawel Wozniak, Managing Director, Komtur Polska

Pawel Wozniak | Managing Director | Komtur Polska » speaking at Orphan Drug Congress

Entela Xoxi, Former AIFA, Universita Cattolica Del Sacro Cuore

Entela Xoxi | Former AIFA | Universita Cattolica Del Sacro Cuore » speaking at Orphan Drug Congress

Stefano Zancan, Head Clinical Development and Operations, Fondazione Telethon

Stefano Zancan | Head Clinical Development and Operations | Fondazione Telethon » speaking at Orphan Drug Congress

Martine Zimmermann, Senior Vice President, Head of Global Regulatory Affairs, Alexion Pharmaceuticals

Martine Zimmermann | Senior Vice President, Head of Global Regulatory Affairs | Alexion Pharmaceuticals » speaking at Orphan Drug Congress

Never Miss An Update

Sign Up for Event Updates